News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

December 3, 2024

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on…

October 28, 2022

Lipidor announces results from the company’s clinical Phase III study of AKP02 for psoriasis

STOCKHOLM 28 October 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study…

October 7, 2022

Emollivet reaches milestone of over 1,000 products sold and prepares for scaled-up production

GOTHENBURG, Sweden, 7th October 2022 – Earlier this year, Lipidor’s subsidiary Emollivet launched Emollivet COMBI – an antiseptic emollient spray for horses…

September 29, 2022

Lipidor updates on Phase III clinical study of psoriasis candidate AKP02

STOCKHOLM, Sweden, 29 September 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that it has updated the…

August 25, 2022

Lipidor appoints new CFO Charlotta Ekman

STOCKHOLM, Sweden, 25 August 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that Charlotta Ekman has been…

August 24, 2022

Lipidor AB (publ) publishes interim report for second quarter 2022

STOCKHOLM, Sweden, 24 August 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…

August 23, 2022

All patients in Lipidor’s Phase III study with psoriasis candidate AKP02 have completed treatment

STOCKHOLM, Sweden – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that all patients included in the company's Phase…

July 11, 2022

Lipidor’s Phase III study of AKP02 for treatment of psoriasis now fully recruited, results expected Q3 2022

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) can today announce that the last patient has been enrolled in the ongoing…

June 2, 2022

Bulletin from the annual general meeting of Lipidor AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor AB (publ) (“the Company”) on 2 June. The…

May 20, 2022

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have…

May 5, 2022

Lipidor AB (publ) publishes interim report for first quarter 2022

STOCKHOLM, Sweden, 5 May 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…